Incorporating Clinical Outcomes and Economic Consequences into Drug Formulary Decisions: A Practical Approach

Greater 340B activity—measured by county-level hospital child sites and contract pharmacy arrangements—was associated with significantly higher county-level total and out-of-pocket health care spending.

The associate editor of Evidence-Based Oncology says the turnover that will follow this week's midterm election calls for renewed engagement from community oncology leaders with members of Congress, due to pressing reimbursement issues.

Medigap Plan F enrollment has declined since it was closed to new beneficiaries in 2020. The percentage of individual Medigap enrollees relative to non–dually eligible traditional Medicare beneficiaries increased from 2013-2024.

Among the therapeutic alternatives used in Medicare’s drug price negotiations, many were generics or biosimilars, and most differed in mechanistic class from the negotiated drug.

In an insured population with advanced lung cancer, clinical trial participants had lower or similar total health care costs compared with nonparticipants.